Open Studies
Open Studies
Our studies are sponsored by the National Cancer Institute (NCI) and affiliated national cooperative research groups, industry, and individual principal investigators (PI).
Study Locations
- SMH: Strong Memorial Hospital
- HH: Highland Hospital
- PR: Cancer Center at Park Ridge
- Sands: Sands Cancer Center
- Pluta: Pluta Cancer Center
| SITE | SPONSOR | LOCAL # | LOCATION(S) OPEN | STUDY TITLE |
| Any | NRG | ARST1321 | SMH | Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613) |
| Brain | RTOG | 1071 | SMH | RTOG1071/N0577(CODEL): Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma |
| RTOG | 3503 | SMH | RTOG 3503 Phase II Trial of Optune® Plus Bevacizumab in Bevacizumab- Refractory Recurrent Glioblastoma |
|
| PI | 70001 | SMH | A prospective pilot study of cognitive changes in patients receiving partial brain radiation: development of a radiation dose-toxicity model for neuroanatomic targets |
|
| Alliance | A221101 | SMH | A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) to Reduce Cancer-Related Fatigue in Patients with High Grade Glioma |
|
| NRG | NRG-BN003 | SMH | NRG-BN003 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma | |
| Breast | RTOG | 1304 | Pluta | NSABP 51_RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary |
| Gastrointestinal | RTOG | 848 | SMH, HH | RTOG 848: A Phase III Trial of Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma |
| RTOG | 1112 | SMH | RTOG 1112: Phase III Study of Sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma | |
| NRG | GI001 | SMH | NRG GI001 Randomized Phase III Study Of Focal Radiation Therapy For Unresectable, Localized Intrahepatic Cholangiocarcinoma |
|
| PI | ULAB11068 | SMH | Analysis of Clinical Data and Lung Dose Using Volumetric Analysis in Patients Treated with Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma | |
| PI | UGIP14107 | SMH, HH | Pilot Study of Short-Course Preoperative Stereotactic Body Radiation Therapy for Resectable Pancreatic Cancer | |
| Genitourinary | NRG | 0924 | SMH, HH | RTOG 0924: Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High-Risk Prostate Cancer: A Phase III Randomized Trial |
| Industry | 56021927PCR 3003 | SMH, HH | Janssen: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 (ARN-509) in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy |
|
| DOD | 59133 | SMH | Risk Prediction for Development of Adverse Effects Following Radiotherapy for Prostate Cancer |
|
| NRG | GU002 | SMH, HH | NRG-GU002 Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel |
|
| Head and Neck | RTOG | 920 | SMH, Sands | A Phase III Study of Postop RT (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer |
| RTOG | 1008 | SMH, HH | A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors |
|
| NRG | HN001 | SMH | NRG HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) |
|
| Lung | RTOG | 538 | SMH, HH | RTOG 538/(CALGB 30610): Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Stage Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide |
| Alliance | A081105 | SMH | A081105 ALCHEMIST EGFR + Randomized Study of Erlotinib vs Observation in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC) |
|
| Alliance | A151216 | SMH, HH, PR, Sands | ALCHEMIST Screening A151216 Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) | |
| ECOG | E4512 | SMH | ALCHEMIST ALK+ A Phase III Trial for Surgically Resected Early Stage Non- Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein |
|
| ECOG | EA5142 | SMH | Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers |
|
| NRG | LU002 | SMH | NRG LU002: Maintenance Systemic Therapy versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Systemic Therapy For Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III trial. |
|
| Metastases from Breast | NRG | BR002 | SMH | BR002: A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer |
| Metastases to Brain | RTOG | 1119 | SMH | RTOG 1119: Phase II Randomized Study of Whole Brain Radiotherapy in Combination with Concurrent Lapatinib in Patients with Brain Metastases from HER2-positive Breast Cancer |
| Metastases to Multiple Organs | NRG | BR001 | SMH | BR001: A Phase I Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases |